C5AR1 and anti-neutrophil cytoplasmic antibody-associated vasculitis: Another oral C5a inhibitor, Avacopan, has just finished its phase III trial, with a better sustained remission rate than corticosteroid at week 52, and obtained the U.S.FDA approval in the maintenance treatment of ANCA associated vasculitis [283].